Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 58, Issue 8, Pages 4527-4534Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02686-14
Keywords
-
Categories
Funding
- Instituto Colombiano para el Desarrollo de la Ciencia y Tecnologia, Francisco Jose de Caldas, COLCIENCIAS
- American Society of Microbiology
- Universidad El Bosque
- National Institutes of Health (NIH-NIAID) [R01 AI093749]
- NIH-NIAID [R01 AI080714, R01 AI047923]
Ask authors/readers for more resources
Daptomycin (DAP) is a lipopeptide antibiotic frequently used as a last-resort antibiotic against vancomycin-resistant Enterococcus faecium (VRE). However, an important limitation for DAP therapy against VRE is the emergence of resistance during therapy. Mutations in regulatory systems involved in cell envelope homeostasis are postulated to be important mediators of DAP resistance in E. faecium. Thus, in order to gain insights into the genetic bases of DAP resistance in E. faecium, we investigated the presence of changes in 43 predicted proteins previously associated with DAP resistance in enterococci and staphylococci using the genomes of 19 E. faecium with different DAP MICs (range, 3 to 48 mu g/ml). Bodipy-DAP (BDP-DAP) binding to the cell membrane assays and time-kill curves (DAP alone and with ampicillin) were performed. Genetic changes involving two major pathways were identified: (i) LiaFSR, a regulatory system associated with the cell envelope stress response, and (ii) YycFGHIJ, a system involved in the regulation of cell wall homeostasis. Thr120 -> Ala and Trp73 -> Cys substitutions in LiaS and LiaR, respectively, were the most common changes identified. DAP bactericidal activity was abolished in the presence of liaFSR or yycFGHIJ mutations regardless of the DAP MIC and was restored in the presence of ampicillin, but only in representatives of the LiaFSR pathway. Reduced binding of BDP-DAP to the cell surface was the predominant finding correlating with resistance in isolates with DAP MICs above the susceptibility breakpoint. Our findings suggest that genotypic information may be crucial to predict response to DAP plus beta-lactam combinations and continue to question the DAP breakpoint of 4 mu g/ml.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available